STRUCTURE THERAPEUTICS INC. - AMERICAN DEPOSITARY

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

17 12 2024 16:01:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

15 11 2024 08:30:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

13 11 2024 16:05:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

13 11 2024 16:01:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024 

31 10 2024 08:30:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

17 9 2024 16:05:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

27 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

26 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

08 8 2024 16:05:01 提供 Nasdaq GlobeNewswire

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares

07 6 2024 16:05:25 提供 Nasdaq GlobeNewswire

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

05 6 2024 19:53:55 提供 Nasdaq GlobeNewswire

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

03 6 2024 16:09:23 提供 Nasdaq GlobeNewswire

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

03 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

09 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

08 3 2024 16:05:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

08 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

18 12 2023 07:30:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

14 11 2023 16:10:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

29 9 2023 07:32:00 提供 Nasdaq GlobeNewswire

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

29 9 2023 07:30:00 提供 Nasdaq GlobeNewswire